


# Revisions to APF25 Cautionary advisory labels



Revisions to Table 2.2 Recommended cautionary advisory labels for medicines  
Revised CAL recommendations for the following medicines are shown in the table below.

Medicine	Revised ancillary label (number) and/or additional instruction (letter)
<b>Atazanavir</b>	4b, 5, B
<b>Chlorpromazine</b>	Oral solution: 1, 8, 9 (long-term regular therapy), 13, 16, 21 Tablet: 1, 8, 9 (long-term regular therapy), 13, 16, 21, A
<b>Melatonin</b>	2, 12, A
<b>Naproxen</b>	Enteric-coated tablet/modified-release tablet: 10a, 12†, 19b, A, B Oral suspension: 10a, 12†, 19b, B, J Tablet: 10a, 12†, 19b, B
<b>Paliperidone</b>	1, 16
<b>Posaconazole</b>	Modified-release tablet: 5, 12, A Oral suspension: 5, 12, B, J
<b>Risperidone</b>	Oral solution/tablet: 1, 16 Orally disintegrating tablet: 1, 13, 16
<b>Terbinafine</b>	Cream/gel/topical solution: K Tablet: 5, 8, 12, 13, D
<b>Teriparatide</b>	6, 7b (28 days), 16†
<b>Ursodeoxycholic acid</b>	Capsule/tablet: 4a (delete dairy products and mineral supplements), A Oral suspension: 4a (delete dairy products and mineral supplements), 7b (4 months), J